Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Bayer's stock price fell to its lowest in nearly 7 years this week, in the wake of a third U.S. jury verdict that found its Roundup weedkiller caused cancer. The plaintiffs were awarded more than $2 billion, the 8th-largest product-defect jury award in U.S. history.
The bottom line: Bayer has lost more than 45% of its equity value since the merger with Monsanto, the maker of Roundup, for which it paid $66 billion. Bayer chose to do away with the Monsanto name and carry products like Roundup under its moniker.
Go deeper: Bayer to appeal latest verdict in Roundup weedkiller cancer claim